Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Danaparoid sodium - Aspen Pharma

Next Previous
X
Search
Drug Profile

Danaparoid sodium - Aspen Pharma

Alternative Names: ORGARAN

Latest Information Update: 20 Dec 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Organon
  • Developer Aspen Pharmacare; Organon
  • Class Antithrombotics
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Heparin-induced thrombocytopenia and thrombosis syndrome
  • Market Withdrawal Deep vein thrombosis

Most Recent Events

  • 08 Dec 2022 Aspen Pharma terminates a phase III trial in Heparin-induced thrombocytopenia and thrombosis syndrome in the US, Bosnia-Herzegovina, Canada, France, Germany, Italy, Poland, Russia, Serbia, Czech Republic, Spain and Croatia (IV, Infusion) due to prolonged delay as a result of impact of Covid19 pandemic (NCT03809481)
  • 22 Apr 2022 Danaparoid sodium is still in phase-III trials for Heparin-induced thrombocytopenia and thrombosis syndrome in France, Poland, Spain, Croatia, Bosnia-Herzegovina, Serbia, Italy, Hungary, Germany, Czech Republic, Canada, USA (IV) (NCT03809481) (EudraCT2018-002473-21)
  • 07 Sep 2020 Mylan enters into an agreement with Aspen to acquire Danaparoid sodium from Aspen in Europe

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top